re: Ann: Dosing Completed in ATL1103 Clinical... Howdy All,This...

re: Ann: Dosing Completed in ATL1103 Clinical... Howdy All,

This P1 trial is to assess the safety, tolerability and pharmacokinetics of ATL1103 administered by injection and is double-blinded… obviously, they have to begin with safety, tolerability and pharmacokinetics because how could they go any further if it was making subjects sick or worse.

Double-blind: Term used to described a study in which both the investigator or the participant are blind to (unaware of) the nature of the study.

IMO after the course of injections are administered and is showing no adverse side effects it is quite indicative and somewhat reassuring of the overall trail results… and it now leaves only a little room for failure thereafter for this stage of the trial. Not wanting to jinx it of course but this announcement is a great sign don’t fooled there will be interest drawn and eyebrows raised by this here clue and milestone.

What has the IGF been doing is the 64 million dollar question… as pointed out in the earlier announcements this was being monitored throughout the course of the study and is what would have been the critical factor in the 'is ALT1103 any good on humans' or not question.

The directors buying these past couple of weeks certainly is writing on the wall how this part must be going.


IMO and Good Luck!